Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Yaron Werber has given his Buy rating due ...
Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...
MilliporeSigma has about 1,700 employees in Wisconsin at facilities in Milwaukee, Port Washington, Sheboygan and in the ...
Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, myasthenia gravis and other conditions traced to misdirected immune response.
Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...
Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...
Sanofi is ending a Phase 2 clinical trial that’s testing a drug from Denali for multiple sclerosis, putting a stop to the development plan. … ...
In this interview, Simon Wieninger discusses the critical role digital tools play in improving bioprocessing efficiency, how ...
These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback